Catalyst Pharmaceuticals Inc (CPRX)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 94,511 | 104,719 | 52,667 | 41,890 | 33,409 |
| Revenue | US$ in thousands | 398,204 | 214,203 | 140,833 | 119,073 | 102,306 |
| Pretax margin | 23.73% | 48.89% | 37.40% | 35.18% | 32.66% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $94,511K ÷ $398,204K
= 23.73%
The pretax margin of Catalyst Pharmaceuticals Inc has varied over the past five years. The pretax margin was at its highest in 2022 at 48.89% and saw a significant decrease in 2023 to 23.73%. This indicates a substantial decline in the portion of revenue that remains as profit before taxes are deducted in 2023. Despite this decrease, the company still maintained a relatively healthy pretax margin compared to the margins in 2021, 2020, and 2019, which ranged from 32.66% to 37.40%.
The fluctuations in the pretax margin may be attributed to changes in revenue, operating expenses, or one-time events impacting the profitability of the company. It is important for investors and stakeholders to closely monitor Catalyst Pharmaceuticals Inc's pretax margin to assess its operational efficiency and profitability levels.
Peer comparison
Dec 31, 2023